These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33933425)

  • 21. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
    Kne A; Zierhut H; Baldinger S; Swenson KK; Mink P; Veach PM; Tsai ML
    J Genet Couns; 2017 Aug; 26(4):697-715. PubMed ID: 27826805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
    Brannon Traxler L; Martin ML; Kerber AS; Bellcross CA; Crane BE; Green V; Matthews R; Paris NM; Gabram SG
    Ann Surg Oncol; 2014 Oct; 21(10):3342-7. PubMed ID: 25047474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist.
    Lynch HT; Snyder CL; Lynch JF; Riley BD; Rubinstein WS
    J Clin Oncol; 2003 Feb; 21(4):740-53. PubMed ID: 12586815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening Familial Risk for Hereditary Breast and Ovarian Cancer.
    Kiser D; Elhanan G; Bolze A; Neveux I; Schlauch KA; Metcalf WJ; Cirulli ET; McCarthy C; Greenberg LA; Grime S; Blitstein JMS; Plauth W; Grzymski JJ
    JAMA Netw Open; 2024 Sep; 7(9):e2435901. PubMed ID: 39320887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".
    Staudigl C; Pfeiler G; Hrauda K; Renz R; Berger A; Lichtenschopf R; Singer CF; Tea MK
    BMC Cancer; 2016 Jul; 16():436. PubMed ID: 27391110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
    Bando H
    Breast Cancer; 2014 Nov; 21(6):656-63. PubMed ID: 23754181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    Rowley SM; Mascarenhas L; Devereux L; Li N; Amarasinghe KC; Zethoven M; Lee JEA; Lewis A; Morgan JA; Limb S; Young MA; James PA; Trainer AH; Campbell IG
    Genet Med; 2019 Apr; 21(4):913-922. PubMed ID: 30254378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer.
    Katapodi MC; Munro ML; Pierce PF; Williams RA
    Nurs Res; 2011; 60(6):368-77. PubMed ID: 22048556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.
    Obstet Gynecol; 2009 Apr; 113(4):957-966. PubMed ID: 19305347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer.
    McDevitt T; Durkie M; Arnold N; Burghel GJ; Butler S; Claes KBM; Logan P; Robinson R; Sheils K; Wolstenholme N; Hanson H; Turnbull C; Hume S
    Eur J Hum Genet; 2024 May; 32(5):479-488. PubMed ID: 38443545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
    Marmolejo DH; Wong MYZ; Bajalica-Lagercrantz S; Tischkowitz M; Balmaña J;
    Eur J Med Genet; 2021 Dec; 64(12):104350. PubMed ID: 34606975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.